Connect with us

Businessuite Markets

Pharma Jamaica Continues To Remain Healthy And Fledgling Towards The US Market Despite Minor Challenges.

Published

on

Dr. Guna Muppuri Chairman of the Board  For Indies Pharma Jamaica Limited has released the following report for the Six-month period ended April 30, 2023.

For the Six-month period ended April 30, 2023, Indies Pharma Jamaica Limited earned gross revenues of J$487 million and J$463 million in the prior comparable quarter of 2022, representing a 5% or J$24.3M increase.

Gross profits for the Six-month period increased to J$339 million, a 1% increase or J$3.6 million when compared to the similar period in 2022.

Cost of Goods Sold (COS) came in at J$20.7M or 16% higher than prior year and was mainly responsible for this relatively flat showing. Marketing samples given out in the trade have been identified as a major contributor (approx. J$12 million) to this increase. The ROI on this “spend” is expected to be realized over the course of the financial year.

Administrative expenses increased by 14% or J$26 million year over year. This was largely driven by increases in Drug permit costs, Admin Salaries, Wages, usual yearly Royalty expense and Administration.

This resulted in the profit from operations declining by J$22.2 million or 14% compared to similar period in 2022. These were largely responsible for Net Profits for the six-month period being J$26.4 million or 23% lower than the corresponding period of 2022.

• Total assets at the end of the six-month period stood at J$2.245 billion, marginally reduced by 0.4% or J$9.5 million from J$2.255 billion in the comparative period last year.
• Shareholders’ equity has increased by 2.2% or J$23.2 million this year to J$1.1billion compared to J$1.07 billion in the prior period 2022 and total liabilities decreased by 3% from J$1.18 billion to J$1.15 billion.
• Earnings per share (EPS) for the six-month period 2023 fell by 22% to J$0.07/share from $0.09/share when compared to the corresponding period last year.

Results For The Second Quarter Ended April 2023

For the second quarter ended April 2023 revenues decreased by $19.1 million (9%) to that of the corresponding period 2022. This is attributed to the late arrival of inventory in April 2023 precluding the timely billing of sales for this quarter impacting the revenues. However, this is expected to be realized in subsequent month / quarter.

In addition to the above, increased market sampling costs leading to a sudden surge in demand for the key product line, leading to early out of stock situation of the “cash cow” products and therefore the delays in the replenishment lead times. This is a new learning opportunity the company has encountered for the first time. This has led the company to reengineer new strategies to deal with this unprecedented interim shortfall and capitalize as the future benefit.

Gross profits for the quarter fell by $14.7 million or 8% to $163.8 million when compared to the previous quarter of 2022. The decrease in Sales revenues combined with the increase in Cost of Sales (COS) are the contributing factors to this decline in Gross Profits.

Administration and Other Expenses increased to $118.7 million for the current quarter in comparison to $99 million in the corresponding quarter in the previous year; this represents an increase of 20%. Contributing factors are due to increases in servicing cost for fleet vehicles and contractual agreement for Bioprist royalty.

Net Profit for the three-month period also declined, by 56% or J$35.8 million to J$28.4 million from J$64.2 million in the corresponding three-month period in 2022. As indicated above, this transient reduction in the profits during this quarter is mainly because of:
• The late arrival of inventory in April 2023 precluded the timely billing of sales for this quarter impacting the revenues which shall be realized in the subsequent month / quarter.
• “Adoption of IFRS 16” leases and reclassification of maintenance expenses.
• Increase in the cost of sales due to writing off the expired goods and increase in the marketing samples budget to capitalize for the future benefit.

Earnings per share (EPS) for the second quarter (for the three-month period) 2023 fell by 60% to J$0.02/share from $0.05/share when compared to the same period last year.

The company has not taken its focus off from managing and implementing strategies to resolutely manage and control expenses and the cost of sales.

The Company continues to remain healthy and fledgling towards the US market despite a few interim minor challenges mentioned above.

The $805 million bond attained in 2020 towards “Growth Capital” continues to remain on the books as we continue to grow the company through the organic development and approval of two new drugs at the USFDA for the United States Market. It should be noted that we successfully submitted our very first ANDA – Abbreviated New Drug Application (generic drug dossier) on the 25 January 2023 at the USFDA. The same was accepted by the USFDA without any rejections or queries on the 24th of February 2023 with a gold date of approval as November 2023.

The product filed at the USFDA is a patent challenge under the paragraph IV filing which has now been accepted and gone unopposed by the innovator drug company on the United States market. This is an incredible development that is destined to reap the benefits for the company from the US market in the immediate short future.

We continue to constantly deliver and maintain a consistent upward trend in our performance and positive outlook. Our hallmark and clarion call of “Caring for the Nation’s Health” and looking out for the welfare of our end users could not have been possible without the dedication of our loyal customers and hardworking employees.

For More Information CLICK THIS LINK

 

Businessuite Markets

GraceKennedy Announces Leadership Changes – Don Wehby Retires; New CEO Announced

Published

on

GraceKennedy Limited has announced key leadership changes, effective February 14, 2025, coinciding with the company’s 103rd anniversary.

After a distinguished tenure, the Honourable Don Wehby, CD, OJ will retire as Group CEO on February 14, 2025, and step down from the Board of Directors. Mr. Wehby joined GraceKennedy in 1995 and was appointed Group CEO in 2011. During his tenure, the company more than doubled in size with revenue moving from J$58 billion in 2011, to J$155 billion in 2023.

Expansion through mergers and acquisitions has been a hallmark of Wehby’s leadership, enabling the company to grow regionally and globally. Under his guidance, it has become one of the largest and most dynamic entities in the Caribbean, with operations spanning the Caribbean, North and Central America, the United Kingdom, and Europe. “I am proud of the progress we have made during my tenure, and I am confident that the new leadership team will take GraceKennedy to even greater heights,” said Wehby. “I want to thank the Board, my colleagues, and our customers for their support over the years,” he added.

Frank James, current CEO of the company’s Domestic Foods Division and former Group CFO, will assume the position of Group CEO on February 14th, 2025, and be appointed to the Board on the same date. Mr. James joined GraceKennedy in 2005 as Vice President of Strategic Planning and Corporate Development. James quickly moved through the ranks, occupying senior roles in both the Food and Financial Services Divisions, before he was appointed Group CFO in 2012. He was also appointed to the Board of Directors that same year. In April 2019, James was appointed Chief Executive Officer, GK Foods Domestic, the largest division in the group of companies, where he has championed growth and efficiency. Under his leadership, revenues for GK Foods Domestic grew by more than sixty percent up to 2023 and continues on that growth path, with even greater growth in profitability over the period.

“I am honoured to take on the role of Group CEO and lead the GraceKennedy team,” said Mr James. “We will continue to focus on delivering value to our customers, shareholders, and the communities we serve,” he added.

Professor Gordon Shirley, Chairman of GraceKennedy Limited, commented, “Don Wehby is an exceptional leader who sees opportunities in challenges and leads by example. We are grateful for his innovative spirit, impeccable work ethic and dedication to ensuring that the company continues to make a difference in the communities we serve. Don’s leadership and vision has been instrumental in shaping the company into what it is today.”

He added, “We welcome Frank to his new role as Group CEO and I have every confidence that his strong leadership will ensure continued growth and innovation across the business. The best is yet to come for GraceKennedy.”

Professor Shirley also expressed his gratitude to Andrew Messado, GraceKennedy Group CFO, for his exemplary leadership during the transition period, following Don Wehby’s temporary leave of absence as Group CEO, in late 2024. The GraceKennedy Chairman noted, “Mr. Messado’s steady hand ensured the company’s continued momentum, and his contributions during this period are gratefully acknowledged.”

These leadership changes are in keeping with the company’s succession plan and are designed to ensure continuity and drive future growth, in line with its 2030 Vision of becoming the Caribbean’s #1 brand with Jamaican roots and a global reach.

GraceKennedy Limited has named Frank James as its new Chief Executive Officer (CEO) as it announced the retirement of Don Wehby from the post.

In October last year, Wehby announced he was taking temporary leave from his role to focus on his health.

In a media release on Tuesday, GraceKennedy said Wehby will retire as Group CEO on February 14 and step down from the board of directors.

Wehby joined GraceKennedy in 1995 and was appointed Group CEO in 2011. During his tenure, the company more than doubled in size with revenue moving from $58 billion in 2011 to $155 billion in 2023.

Professor Gordon Shirley, Chairman of GraceKennedy Limited, commented, “Don Wehby is an exceptional leader who sees opportunities in challenges and leads by example. We are grateful for his innovative spirit, impeccable work ethic and dedication to ensuring that the company continues to make a difference in the communities we serve. Don’s leadership and vision has been instrumental in shaping the company into what it is today.”

James, who is the current CEO of the company’s Domestic Foods Division and former Group Chief Financial Officer, will assume the position of Group CEO on February 14 and be appointed to the board on the same date.

James joined GraceKennedy in 2005 as Vice President of Strategic Planning and Corporate Development. He quickly moved through the ranks, occupying senior roles in both the Food and Financial Services Divisions, before he was appointed Group CFO in 2012. He was also appointed to the board of directors that same year.

In April 2019, James was appointed Chief Executive Officer, GK Foods Domestic, the largest division in the group of companies, where he has championed growth and efficiency. Under his leadership, revenues for GK Foods Domestic grew by more than 60 per cent up to 2023.

In commenting on his new role, James. said, “We will continue to focus on delivering value to our customers, shareholders, and the communities we serve.”

Continue Reading

Businessuite Markets

Who Is Frank James New Chief Executive Officer (CEO) Of GraceKennedy Limited?

Published

on

Frank James has been appointed as the new Chief Executive Officer (CEO) of GraceKennedy Limited, effective February 14, 2025, succeeding Don Wehby, who is retiring after a distinguished tenure.

Professional Journey at GraceKennedy

James joined GraceKennedy in August 2005 as Vice President of Strategic Planning and Corporate Development for the Information Services Division.
In December 2006, he became Principal of GK Investments, now known as GraceKennedy Financial Group.

His career progression included a secondment to GK General Insurance Company in April 2010 and a subsequent role in the Corporate Finance and Accounting Department in November 2010.

In 2012, James was appointed Group Chief Financial Officer (CFO) and joined the Board of Directors.

In April 2019, he became CEO of GK Foods Domestic, the company’s largest division, where he led significant growth, with revenues increasing by more than 60% up to 2023.

Educational Background and Early Career

James holds an undergraduate degree from the University of the West Indies, Mona, and an MBA from UCLA Anderson School of Management.

Before joining GraceKennedy, he gained experience at Desnoes & Geddes Ltd. and PricewaterhouseCoopers Jamaica.

Leadership Philosophy and Vision

Known for his strong financial acumen and strategic planning skills, James has been instrumental in driving efficiency and growth within GraceKennedy’s domestic food operations. As he steps into the role of Group CEO, he emphasizes a commitment to delivering value to customers, shareholders, and communities.

Personal Life

James is a family man who places God first in his life. He is an alumnus of Wolmer’s Schools, reflecting his deep roots in Jamaican education.

Community Engagement

Beyond his corporate responsibilities, James is actively involved in community development initiatives. He has participated in campaigns encouraging positive change, such as the “Graceful Wish” project, which aims to make a difference in local communities.

Frank James’s appointment marks a new chapter for GraceKennedy Limited, with expectations that his leadership will continue to drive the company’s growth and commitment to excellence in the years ahead.

Continue Reading

Businessuite Markets

RJR Group Continues To Be Negatively Impacted By Softness In Advertising Market

Published

on

Q2 2024 (Ended September 30, 2024 ) continued to be impacted by both local and international challenges, inflation and increased costs. The Group continued to experience softness in the overall advertising market as businesses repotted the continued impact of local and global economic conditions. The Group’s advertising revenues were more than last year due to the broadcast of the Olympic Games in July and August 2024. The quarter was also impacted by some one-off costs of approximately $25 million incurred related to restructuring expenditure as part of the move to a new target operating model (TOM)

The Group recorded a pre-tax loss of $1 18 million and an after-tax loss of $103 million for the quarter, compared to a pre-tax loss of $79 million and an after-tax loss of $65 million for the prior year period. This profit performance represents an improvement over the quarter to June 2024 where the pre- and post-tax losses were $183 million and $167 million, respectively. This loss reduction is directly attributable to the Implementation of cost management strategies and efforts to ensure that advertising revenues were maximized from programmes aired during the period.

Primary contributors to this quarter’s performance, compared to prior year were:

  • An overall improvement of $56 million (3.9%) in the Group’s revenues, driven mainly by an increase in the Broadcast Division revenues associated with the airing of the Olympic Games (for which the company held the broadcast rights for Television only).
  • A decline in revenue in the Audio segment of $24.5 million (12%); a result of the pressure on advertising budgets, highlighting the need to find new strategies to attract businesses to this medium
  • A decrease in other income of $7million (17%), as a result of a reduction in income from noncurrent investments held.
  • An increase in direct expenses of $73 million (10.8%), due to the increased costs associated with the broadcasting of the Olympic Games,
  • An increase in selling expenses of $13.9 million (5.2%), commensurate with increased revenues.
  • An increase in administrative expenses of $2.4 million (0.6%) which was offset by the reduction in other operating expenses by $5.6M (2.6%). The containment in costs is a result of cost-saving initiatives that have been implemented. The expense movement was driven primarily by increases in staff-related costs, insurance costs and higher depreciation expenses relating to investments in infrastructure upgrades. While there has been an overall loss in the quarter, the Group continues to implement measures that will lead to further cost reductions through restructuring our expenditure profile as part of the move to a new target operating model (TOM).

Management continues to focus on the implementation of the five strategic imperatives designed to return the Group to sustained profitability. Implementation of the web-based top-up product (partnering with an overseas entity) will be completed in the next quarter Implementation of the NCB Go rewards platform is one of the most significant revenue diversification opportunities and we are hoping to launch the platform in the fourth quarter of the financial year. Initiatives relating to the digital transformation of our products are also being pursued for future revenue impact.

The Group will continue to focus on increased presence and influence in the digital space while producing content that fulfills the needs of the market.

 Anthony Smith Chief Executive Officer RJRGLEANER Communications Group (the Group) 

For More Information CLICK HERE

Continue Reading

Businessuite Markets

Fontana Reporting Comparative Q1 Revenue Jump of 16.2%, Q2 Anticipated To Be Best Yet!

We saw increased revenues in all our locations, including our newest store in Portmore which has largely maintained their break-even monthly sales. Transaction counts, average spend per customer, and prescription counts continue to show month over month gains as we grow our footprint in St. Catherine.

Published

on

Income Statement
Our revenue for the quarter was $2.07 billion, representing an increase of 16.2% over the $1.78 billion for the corresponding quarter of the previous year. Operating profit grew by 26.9%, going from $80.8 million to $102.6 million. Despite increased income tax liabilities (see below), net profit for the quarter was $60.5 million, or 1.5% less than that reported for the same period last year.

We saw increased revenues in all our locations, including our newest store in Portmore which has largely maintained their break-even monthly sales. Transaction counts, average spend per customer, and prescription counts continue to show month over month gains as we grow our footprint in St. Catherine.

Cost of sales increased by 9.9% (compared to 16.2% for revenues) resulting in gross profit moving from $603.2 million to $774.5 million, a 28.4% increase over Q1 last year. Our efforts to capitalize on economies of scale within our procurement and inventory management activities, resulted in a higher gross margin of 37.5%, up from 33.9% in the prior year.

Operating expenses grew by 28.6%, ending the quarter at $671.9 million compared to $522.3 million last year. This was partly attributable to the opening of our Portmore store in November 2023, along with increased staff costs across the network. As we continue to focus on staff retention, engagement and satisfaction, costs and benefits contributed to 58% of the operating expenses increase over last year. Provisions were also made for senior staff retiring in 2025, some with over 50 years of service. We continue to make inroads into industrial security and insurance rates, as well as improve on our conservation efforts as we saw increases in our utilities.

Finance costs saw an increase of 25.3%, moving from $52.6 million in Q1 last year to $65.9 million this quarter, this was mainly attributable to foreign exchange losses on the lease liability (IFRS16) as well as the new store. Other income also grew by 7.7% ending the quarter at $35.7 million as we seek to tap into new revenue streams in the Portmore store.

Fontana Pharmacy has now been listed on the Junior Stock Exchange for 5 years as at January 2024. This achievement means that we now have liability to corporate income taxes, which required a provision of $11.9 million for the quarter. Earnings per share remained constant at $0.05 for both comparable quarters.

Balance Sheet
Total assets at the end of the quarter stood at $5.6 billion, up from $5.2 billion in the previous comparative period, reflecting an increase of 6.2%.
Our cash and cash equivalents remain favorable at $1.2 billion, 4% less than the previous comparative period, this is after the August 2024 dividend payment of $312.3 million. Shareholder’s equity grew to $2.7 billion, up from $2.5 billion or 6.1% over the prior corresponding quarter. This puts us in a strong position to pursue further expansion opportunities as they come up.

Outlook
At the end of this quarter, we were far advanced in the development and adaptation of 2 efficiency tools:
PIMS integrated point of sale system for the pharmacy department – accommodating patient profile access across all stores, adding to the efficiencies for central ordering and inventory management A new integrated HR software – improve efficiencies as well as enhance the experience of team members. Faster processing times, better data analytics and a reduction in errors is expected.

We continue to invest in technology that will improve our efficiency and contribute to a better control environment.
These two initiatives are the ones among the many that keep us relevant and differentiated from our competitors. We are cognizant of the ongoing impact of Hurricane Beryl on the Jamaica’s economic landscape. Early indicators such as the softening of demand for non-essential home items, toys and home décor have been noted. We will continue to monitor these indicators and implement the required strategies to manage the potential impact.

At 7 stores strong, the organization is experiencing a tremendous period of growth and development, well positioned as one of the most recognized retail brands in Jamaica and the premier pharmacy chain across the country. Our second quarter is anticipated to be the best yet!

Anne Chang Director CEO Fontana Limited 

For More Information CLICK HERE

Continue Reading

Businessuite Markets

Despite Growing Losses RA William’s Still Has A Positive Future Outlook

RA William’s gross profit increased by 14%, mainly driven by the introduction of new products across several of our product lines. We recorded a net loss before tax for the quarter of $13.9M, compared to a net loss of $792K for the same period last year.

Published

on

RA William’s gross profit increased by 14%, mainly driven by the introduction of new products across several of our product lines. We recorded a net loss before tax for the quarter of $13.9M, compared to a net loss of $792K for the same period last year.

Our operating expenses ratio for this quarter stands at 45%, up from 38% in the prior year. This increase is primarily attributed to the right of use costs related to our new location at New Brunswick Village, as well as higher technology, staffing, and distribution expenses.

We achieved a revenue of $367M which represents a 0.95% increase compared to the same quarter of the previous year. During this period, we encountered significant challenges, including supply constraints in certain product categories and the effects of Hurricane Beryl, which disrupted operations for many of our key customers, particularly along the south coast.

There was an increase in total assets, of $1.4B. The increase in assets reflects our strategic investments in infrastructure, including the opening of our new office and warehouse at the beginning of the quarter. These investments position us to expand our partnerships with pharmaceutical manufacturers and further strengthen our business.

Enhanced Product Portfolio And New Distribution Channels

Our ongoing efforts to enhance distribution channels, collaborate with stakeholders to manage supply and demand, and fortify our position in a competitive market have allowed us to navigate these challenges effectively. Looking ahead, we anticipate revenue growth driven by the reintroduction of key products under our newly added Fourrts line, expected early in the third quarter.

During the quarter, we were proud to add several new products to our portfolio. Notably, we introduced ColdStop (an over-the-counter day & night cold and flu pack), GasStop (an over-the-counter antacid), and DandZap Plus (a prescription shampoo for dandruff and seborrheic conditions), in partnership with Canadian-based Ryvis Pharma. These additions reflect our ongoing commitment to expanding our market offerings and increasing our market share.

RA Williams remains committed to being a responsible corporate citizen, with a strong focus on education and health and wellness. This quarter, we deepened our support for pharmacists and pharmacy professionals through our sponsorship of the Pharmaceutical Society of Jamaica’s Annual Conference – the premier pharmaceutical event in the English-speaking Caribbean. Our sponsorship provided an opportunity to network with industry professionals, and we also hosted a soft launch for Iracet, the first generic Levetiracetam available in Jamaica, in collaboration with our long-time pharmaceutical partner, Square Pharmaceuticals,
as part of a workshop on epilepsy. Additionally, we sponsored the University of Technology’s School of Pharmacy Pinning Ceremony, where a house was named in honour of our Founder and Chief Quality Officer, Evelyn Williams. These initiatives are a testament to our ongoing commitment to the next generation of pharmaceutical professionals.

Positive Future Outlook
We are encouraged by our continued revenue growth and the expansion of our product portfolio. RA Williams continues to be a preferred distributor to pharmacies and healthcare professionals. Our focus remains on expanding our offerings and improving the customer experience. We are confident in our ability to continue improving access to high-quality, affordable medications in the months ahead.

Audley Reid Managing Director R.A. Williams Distributors Limited

For More Information CLICK HERE

Continue Reading

Trending

0
Would love your thoughts, please comment.x
()
x